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INTRODUCTION
Churg-Strauss syndrome (CSS) is a necrotizing systemic
vasculitis which affects the small- to medium-sized blood ves-
sels and is characterized by asthma, eosinophilia and extravas-
cular eosinophilic granulomas (1). This disorder occurs in all
age groups but has been reported most commonly in the third
to fifth decades of life. The mean estimated incidence has been
reported to be 2.4-6.8/1,000,000 in the general population,
and 64.4/1,000,000 in asthma patients (2, 3). The prevalence
is 13/1,000,000 in the general population, compared with 33/
1,000,000 for polyarteritis nodosa (PAN) and 53/1,000,000
for Wegener’s granulomatosis (WG) (4).
Most of previous reports regarding CSS in Korea have been
case reports (5-8). Although the effect of intravenous pulse
cyclophosphamide (CPM) in the treatment of CSS with refrac-
tory neuropathy to high-dose steroid treatment was reported
(9), there have been no large single center studies of CSS pa-
tients reported in Korea.
The presentation and course of CSS are highly variable; ma-
nifestations may range from mild (asthma, sinusitis, cutaneous
lesions) to life-threatening conditions (severe gastrointestinal
[GI] involvement, heart failure, disabling neuropathy). Fur-
thermore, diagnosis of CSS can be difficult because the mani-
festations vary with the disease stage. CSS is manifested in
three consecutive phases: a prodromal phase consisting of
allergic manifestations; a second phase of peripheral blood
eosinophilia and eosinophilic tissue infiltrates; and a third
phase consisting of vasculitic systemic manifestations (10).
Treatment delay in the vasculitic phase may lead to irrever-
sible major organ damage.
Here, we described 17 patients with CSS diagnosed at our
Department of Medicine between 1995 and 2004. We ana-
lyze the clinical features, responsiveness to treatment, and
long-term outcome.
MATERIALS AND METHODS
Subjects
Seventeen patients with CSS were selected from the Depart-
ment of Medicine of the Samsung Medical Center, Sungkyun-
kwan University School of Medicine, between 1995 and 2004.
Clinical data were obtained from outpatient and/or inpatient
medical records.
The diagnosis was made when four or more of the Ameri-
can College of Rheumatology classification criteria were ful-
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Churg-Strauss Syndrome: The Clinical Features and Long-term 
Follow-up of 17 Patients
Churg-Strauss syndrome (CSS) is a rare multi-system vasculitis; some cases have
been reported in Korea. The aim of this study is to describe the clinical features, treat-
ment outcome, and long-term follow-up of CSS from a single Korean medical cen-
ter. Between 1995 and 2004, seventeen patients were diagnosed with CSS at the
Department of Medicine of the Samsung Medical Center, Sungkyunkwan University
School of Medicine. The diagnosis of CSS is based on the classification criteria of
the American Collage of Rheumatology. All patients had asthma. As in other case
series, the lung, peripheral nervous system, and skin were the most commonly in-
volved organs. During the active stage of the disease, most of the patients exhibit-
ed peripheral blood eosinophilia and an elevated serum eosinophil cationic protein
level. Ten patients were treated with pulses of methylprednisolone followed by taper-
ing and cyclophosphamide, and the others were treated with corticosteroids alone.
The outcomes after long-term follow-up were generally good. One patient who was
refractory to initial treatment died of heart failure during the follow-up period. CSS
was highly variable in its presentation and course. The manifestations may range
from mild symptoms to life-threatening conditions. The outcome after long-term fol-
low-up was as good as that of previous studies.
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filled. These criteria include asthma, peripheral blood eosino-
philia (>10% on differential white blood cell count), mono-
neuropathy or polyneuropathy, pulmonary infiltrates, para-
nasal sinus abnormality, and a biopsy finding containing a
blood vessel with extravascular eosinophils.
Asthma was diagnosed on the basis of symptoms, measure-
ments of reversibility of lung function abnormalities, and air-
way hyperresponsiveness by methacholine bronchoprovoca-
tion test.
Peripheral neuropathy consisted of mononeuropathy includ-
ing mononeuritis multiplex and polyneuropathy. Central ner-
vous system (CNS) involvement was considered when central
neurologic manifestations occurred and could not be attribut-
ed to metabolic disorders or stroke.
Myocardial involvement was considered to be due to CSS
when cardiac insufficiency occurred in the absence of preexis-
tent risk factors such as coronary heart disease, valvular dis-
ease, hypertension, diabetes, and toxic or infectious agents
and/or when histologically proven by examination of a myo-
cardial biopsy.
GI involvement was considered when unexplained abdomi-
nal pain, intestinal bleeding, intestinal perforation, cholecys-
titis or pancreatitis was present without other pathogenic
explanation.
Renal involvement was defined as the presence of unexplai-
ned increase in serum creatinine, proteinuria >1 g/day, abnor-
mal urinary sediment and/or histologic findings in a renal
biopsy consistent with systemic vasculitis.
The therapeutic regimen
In cases of severe, life-threatening, multi-system involve-
ment (e.g., heart failure, severe GI involvement or disabling
neuropathy), the patient treated with pulses of methylpred-
nisolone followed by tapering and CPM. Intravenous pulses
of CPM (500-750 mg/m
2) were administered at a total of six
pulses at one-month interval. Depending on the clinical sta-
tus of the patient, further pulses could be administered. At 2
weeks after every pulse CPM, routine blood tests were per-
formed to examine cytopenia and presence or absence of liver
and renal dysfunction. For maintenance therapy, low-dose
prednisolone was orally administered according to the clinical
manifestations and results of laboratory testing.
A patient was considered to be in remission when the clini-
cal manifestations disappeared for a period of at least 6 mon-
ths. However, neurologic sequelae could persist. A relapse
was defined as the recurrence of clinical manifestations of CSS
other than asthma or isolated eosinophilia.
RESULTS
Demographic data
Between 1995 and 2004, 17 patients (9 men, 8 women)
were diagnosed with CSS in our department. The mean age
at the time of diagnosis was 36.7 (range from 24 to 53) yr.
The patients were followed for a mean period of 42.5 (range
Case Sex
Time lapse 
BA-CSS (yr)
Involved 
organs PB eosinophil
(/ L)
Laboratory findings
ECP
(ng/mL)
ESR
(mm/hr)
Follow-up 
periods
(months)
Treatment
ANCA
Age (yr)
1 F 53 15 N, S 7,875 118 15 - CS+CPM 46
2 M 28 18 L, S 2,436 492 25 - CS 57
3* F 39 3 L, S 378  72.2 32 - CS 53
4 F 40 5 L, G 2,983 NC 2 - CS 36
5 M 37 3 N, S 4,712 342 16 - CS+CPM 85
6 F 50 10 N, S 310 339 27 - CS+CPM 89
7 M 29 1 L, N, G, C 1,876 NC 77 - CS+CPM 21
8 F 40 3 N, S 12,350 NC 33 - CS+CPM 113
9 F 43 2 N, S 1,776 1,490 25 + CS+CPM 79
p-ANCA
10 M 24 1 L, N 5,250 66.3 2 - CS+CPM 27
11 M 50 10 L, N, C 5,100 86.5 6 - CS+CPM 26
12 M 32 4 L, N, S, G 2,133 78.4 57 - CS+CPM 26
13 M 28 6 L, N 13,940 40.7 49 - CS 19
14 F 25 4 L 8,930 215 48 - CS 14
15 M 29 2 L, S 5,050 NC 39 - CS 12
16 F 26 0 S, C 6,920 181 28 - CS 11
17 M 51 1 L, N 4,430 114 60 - CS+CPM 8
Mean±SD 36.7±10.0 5.18±5.15 5085.2±3906.7 279.6±388.2 31.2±21.8 42.5±32.0
Table 1. Clinical and laboratory features in 17 patients with Churg-Strauss syndrome
BA, bronchial asthma; CSS, Churg-Strauss syndrome; PB, peripheral blood; ECP, eosinophil cationic protein; ESR, erythrocyte sedimentation rate;
ANCA, anti-neutrophil cytoplasmic antibodies; L, lung; N, nervous system; S, skin; G, gastrointestinal system; C, cardiovascular system; NC, not checked;
p, perinuclear; CS, corticosteroids; CPM, cyclophosphamide. *These cases were already undergoing treatment with corticosteroids. Data are expressed
as Mean±SD.Clinical Features of Churg-Strauss Syndrome 267
tremities. Skin biopsies were performed in 9 patients. Vasculi-
tis was found in 6 biopsies, eosinophil infiltrates in 2 biop-
sies, and lymphocyte infiltrates in 1 biopsy.
GI involvement was seen in 3 patients (17.6%). In the first
case (case 4) with recurrent epigastric pain, hemorrhagic gas-
tritis was found on gastroendoscopy. In the second case (case
7), which presented with diarrhea, hemorrhagic erosions were
found on colonoscopy and, on mesenteric angiography, throm-
bosis was found in the inferior mesenteric vein. In the third
case (case 12) with severe acute abdominal pain, emergency
laparotomy was performed and revealed peritonitis and per-
foration of the small intestine. Intestinal biopsy in the third
case showed ulcer with granulation tissue, congested vessels,
and mixed infiltration of inflammatory cells with a predom-
inance of eosinophils.
Three patients (17.6%) presented with congestive heart
failure with 2 patients showing a small amount of pericardial
effusion (Table 4). A case 16, young woman was treated with
corticosteroids alone with consideration of the possibility of
pregnancy; the other 2 patients were treated with corticos-
teroids and CPM. A case 16 underwent coronary angiogra-
phy with endomyocardial biopsy. No evidence of coronary
artery disease was detected, but hypokinesia of the apex and
anterolateral wall was noted. Histology showed focal myocar-
ditis with prominent interstitial eosinophilic infiltration with-
out vasculitis.
Laboratory findings
At the time of diagnosis, peripheral blood eosinophilia was
present in 15 patients. Those without blood eosinophilia were
already undergoing treatment with corticosteroids. The mean
blood eosinophil count of all patients was 5085.2/ L (refer-
ence value <500/ L). Eosinophil cationic protein (ECP) level
was checked in the sera of 13 patients, all of whom exhibited
elevated serum ECP level at the time of diagnosis; the mean
value was 279.6 ng/mL (reference value<16 ng/mL). Anti-
neutrophil cytoplasmic antibodies (ANCA) were tested in all
patients and myeloperoxidase-ANCA were detected in 1 pa-
tient at the time of diagnosis.
Chumbley
et al. (17)
(1950-1974)
Lanham 
et al. (10)
(1976-1982)
Guillevin
et al. (16)
(1963-1995)
Present study
(1995-2004)
Della Rossa 
et al. (14)
(1989-2000)
Solans 
et al. (15)
(1977-1999)
Type of study Single center Single center Single center Single center Single center Single center
retrospective retrospective prospective retrospective/ retrospective retrospective
prospective
No. of patients 30 16 96 32 19 17
M/F ratio 2.3 3 0.88 0.3 0.9 1.1
Mean age (yr) 47 38 48.2 42.5 46 36.7
Age range (yr) 15-69 ND 14-74 17-85 24-78 25-53
Clinical manifestations (%)
Asthma 100 100 100 100 100 100
Generalized symptoms ND 87 70.8 68.8 89.4 76.5
Pulmonary infiltrates  26.7 75 37.5 53.1 58 64.7
Peripheral nervous system  63.3 75 78 68 57.8 64.7
Skin 66.7 69 51 68.8 63 58.8
Gastrointestinal 16.7 56 33 37.5 47.3 17.6
Heart 16.7 25 35.4 28.1 31 17.6
Kidney 0.3 50 26 12.5 21 0
ESR high high high high high high
Eosinophilia present present present present present present
ANCA (%) NC NC 38 77 35 5.9
Table 5. Comparison of data from the present study with data from previous studies
ESR, erythrocyte sedimentation rate; ANCA, anti-neutrophil cytoplasmic antibodies; ND, not documented; NC, not checked.
10/17 7/17
MPD pulse+CPM CS alone
1/5 Increased
doses of CS+CPM
Require further follow -up
4/5
Increased doses of CS
Remission with low 
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11/16 Remission
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Treatment failure
Death
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Oral CPM
16/17
Remission
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Relapse
Fig. 1. Therapeutic modalities and disease course of 17 patients
with Churg-Strauss syndrome. MPD, methylprednisolone; CPM,
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Disease course and long-term follow-up
Fig. 1 summarizes the therapeutic modalities and disease
course of 17 patients with CSS.
Ten patients were treated with pulses of methylprednisolone
followed by tapering and CPM. The other patients were treat-
ed with corticosteroids alone. Nine patients were administered
on average 7.3 intravenous pulses of CPM; one patient was
administered oral CPM. The serious adverse effects of CPM,
such as hemorrhagic cystitis, bone marrow suppression, and
neoplasm, were not documented during the follow-up peri-
od. One patient was refractory to the initial treatment and
was subsequently placed on alternative pulses of methylpred-
nisolone and oral CPM, but the patient did not comply with
the treatment regimen and eventually died of heart failure.
Five patients suffered relapses during the follow-up period
and the clinical manifestations noted at the time of relapse
were similar to those at the time of diagnosis. A suspected
triggering factor for the relapses was the rapid tapering or dis-
continuation of corticosteroids treatment in 4 patients. At the
time of the last visit, 13 of the 16 survivors in this study still
required low doses of oral prednisolone (mean dose of 7.4 mg/
day), 2 patients sustained remission without corticosteroids,
and 1 patient required further follow-up.
DISCUSSION
CSS is a rare disorder characterized by eosinophilia and sys-
temic vasculitis and almost invariably occurs in patients with
asthma. Vasculitis commonly affects the lung, peripheral
nerves, skin, heart, and GI tract. Renal involvement is not a
necessarily characteristic of this disease, but it may occur in
some cases (11).
The clinical spectrum of PAN or microscopic polyangiitis
is similar to that of CSS, but the patients with PAN have no
asthma, eosinophilia, or history of atopy. Additionally, patients
with PAN have a higher frequency of nephritis, bowel vasculi-
tis, and hypertension than do patients with CSS (12). The dif-
ferentiation of these diseases may be important because CSS
has a better rate of long-term remission than PAN when cor-
ticosteroid treatment was introduced (12, 13).
This is the first study to observe the clinical characteristics
of CSS patients based on Korean experience in a single cen-
ter over a 10-yr period. Table 5 shows data from the present
study in comparison with those from previous studies.
The mean age of patients at disease onset was a little youn-
ger than that documented in previous studies (10, 14-17).
The clinical and laboratory features seen in the present study
was similar to that in the largest previous studies except that
renal involvement and ANCA were demonstrated less fre-
quently (10, 14-17).
As in previous studies, asthma was present in all the study
patients and preceded CSS development in all patients but
one, in whom asthma began simultaneously with CSS. A pul-
monary infiltrates was present in 64.7% of patients. The most
frequent findings of HRCT were consolidations in patchy or
diffuse distribution and bronchial wall thickening. Worthy
et al. (18) reviewed the HRCT findings in 17 patients with
CSS. The most common abnormality consisted of bilateral
consolidation or ground-glass attenuation in either patchy or
predominantly peripheral distribution. Choi et al. (19) revie-
wed the HRCT findings in 9 patients with CSS. The most
common findings included bilateral ground-glass opacities,
centrilobular nodules mostly within the ground-glass opaci-
ties, and bronchial wall thickening.
Peripheral nerve involvement, present in 64.7% of patients,
was the most frequent manifestation; its frequency in the pre-
sent study was comparable to those seen in previous studies.
Also as in previous studies, mononeuritis multiplex consti-
tuted the most frequent manifestation of peripheral nerve
involvement and the peroneal nerve was the most frequently
involved (20-22). All patients responded well to corticoste-
roids and CPM therapy, although 4 patients had residual
symptoms, such as hypesthesia or neuropathic pain, some-
times associated with mild motor deficit. However, the symp-
toms were not severe in any of these cases. No involvement
of the CNS was noted in the study subjects. CNS involvement
may include palsies of the cranial nerves, cerebral hemorrhage
or infarction, convulsions, and psychosis, but these occurrences
are atypical. When CNS involvement dose occur with CSS,
it causes significant morbidity and mortality (10, 23).
Skin involvement was present in 58.8% of patients, with
palpable purpura presenting as the most frequent manifes-
tation, as in previous studies (10, 14-17).
GI involvement was less frequent than in previous studies.
Pathophysiology of GI involvement in CSS is known ischemic
change from vasculitis and bowel wall infiltration with eosi-
nophils (24). Churg and Strauss (1) described 12 of 13 pa-
tients with CSS with abdominal pain or diarrhea, one of whom
died of intestinal perforation from ulceration. GI involvement
in CSS, such as abdominal pain, diarrhea, intestinal bleeding,
and intestinal obstruction was present in 37-62% of patients,
as reported by other authors (10, 16, 17, 25).
In 17.6% of patients, cardiac manifestation was present. A
case 16 showed striking improvement in left ventricular func-
tion (LVEF 54%) with improvement of hypokinesia on ini-
tial treatment. A case 11 relapsed at the eighth month and
responded to increased doses of corticosteroids with conser-
vative management, but case 7 was refractory to treatment
and died of heart failure. Cardiac involvement includes eosi-
nophilic endomyocarditis, coronary vasculitis, valvular heart
disease, congestive heart failure, hypertension, and pericardi-
tis (1, 11, 23, 26). In previously reported cases, treatment
ranged from relatively high doses of corticosteroids to low
doses combined with digoxin and diuretics. However, when
immunosuppressive agents, especially CPM, were added to
the treatment, it was found to be effective and to improve theClinical Features of Churg-Strauss Syndrome 269
from 8 to 113) months.
Clinical features and histologic findings
Clinical and laboratory features of 17 patients with CSS
are listed in Table 1 and the histologic findings in biopsies
of 14 patients with CSS are detailed in Table 2.
Non-specific symptoms consisting of malaise, weight loss,
fever, and arthromyalgia marked the early stages of vasculitis
in 13 of 17 patients (76.5%).
All patients had asthma.  The mean time lapse between
the appearance of asthma and the onset of vasculitis was 5.18
(range from 0 to 18) yr. In 15 patients, asthma began when
the patient was an adult (mean age 32.4 yr). Two patients had
recent-onset asthma of less than 6 months, 1 of whom had
asthma as presenting symptom of CSS. In 8 of 17 patients
(47.1%), asthma was severe and had necessitated oral corticos-
teroids frequently. Mechanical ventilation was needed for sta-
tus asthmaticus at the presentation of CSS in 1 patient. The
upper respiratory tract was affected in 11 patients (64.7%).
These patients complained rhinorrhea, nasal obstruction, and
postnasal drip; sinusitis was demonstrated in paranasal sinus
radiography. Three of these patients required endoscopic
sinus surgery. The lower respiratory tract was also affected in
11 patients (64.7%). Transient pulmonary infiltrates were
detected by chest radiography or high-resolution computed
tomography (HRCT) scan. The infiltrates were various such
as nodules, ground glass opacities, consolidations, and bron-
chial wall thickening in patchy or diffuse distribution with
no preferred location. Three patients had hemoptysis. Alve-
olar hemorrhage was detected by the findings of bronchoalve-
olar lavage in 2 patients and 1 patient presented with acute
respiratory failure. One patient had polymorphonuclear cell-
dominant exudative pleural effusion and the finding upon
pleural biopsy was mesothelial hyperplasia with infiltration
of numerous eosinophils and plasma cells. Transbronchial
lung biopsies or video-assisted thoracoscopic biopsies were
performed in 5 patients. Eosinophilic vasculitis was found in
1 biopsy and vascular and interstitial eosinophil infiltrates
were found in 4 biopsies
Eleven patients (64.7%) showed signs of peripheral nerve
involvement without involvement of the CNS (Table 3). This
manifestation was asymmetric and distal-dominant fashion.
Electroneurography revealed mononeuritis multiplex most
commonly. The most frequently involved nerve was the per-
oneal nerve, followed by tibial, sural, median, and ulnar nerves.
Sural nerve biopsies were performed in 7 of 11 patients. Six
showed vasculitis (one with fibrinoid necrosis, five with peri-
vascular infiltrates) and the other showed axonal degeneration
without vasculitis.
Ten patients (58.8%) experienced cutaneous manifestations:
palpable purpura, papules, urticarial rash, vesicles, aseptic
pustules, and Raynaud phenomenon. This manifestation typi-
cally involves the distal limbs, most frequently the lower ex-
Biopsy site No.
Vasculitis
(No.)
Eosinophil infiltration
without vasculitis (No.)
Other findings
(No.)
Skin 9 6 2 1
Nerve 7 6 0 1
Lung 5 1 4 0
Pleura 1 0 1 0
Myocardium 1 0 1 0
Jejunum 1 0 1 0
Total 24 13 9 2
Table 2. Histologic findings in biopsies of the 14 patients with
Churg-Struass syndrome 
NCS, nerve conduction study; RU, right upper extremity; RL, right lower
extremity; LL, left lower extremity; BU, both upper extremity; BL, both
lower extremity; d, distal; p, proximal.
Case
Symptom
Sensory Motor
Symptom
distribution
NCS finding
1 pain foot drop BU (d), BL (d) distal poly
neuropathy
5 tingling, BU  (d) mononeuro-
numbness pathy
6 pain,  hand grip weak- RU (d), LL (d) mononeuritis 
numbness ness, foot drop multiplex
7 pain, foot  drop BL  (d) mononeuritis 
numbness multiplex
8 tingling,  hand grip weak- RU (d), BL (d) mononeuritis 
numbness ness, foot drop multiplex
9 tingling hand grip weak- BU (d), BL (d) mononeuritis 
ness, foot drop multiplex
10 tingling, BL  (d) mononeuro- 
numbness pathy
11 pain  foot drop BL (d) distal poly
neuropathy
12 tingling hand grip  RU (d), LL (p) mononeuro-
weakness pathy
13 numbness RL (d) mononeuritis 
multiplex
17 pain,  foot drop BU (d), BL (d) mononeuritis 
numbness multiplex
Table 3. Clinical features and electrodiagnostic findings in 11
Churg-Strauss syndrome patients with peripheral nerve involve-
ment
Case ECG Echocardiogram
7 RBBB Focal thickness of endocardium,
LVEF 35-40%, minimal pericardial effusion
11 VPC  Enlargement of the chambers,
RAE LVEF 22%, moderate mitral regurgitation
16 RBBB Global hypokinesia with RWMA,
LVEF 30-35%, mild pericardial effusion
Table 4. Electrocardiography and echocardiogram in 3 Churg-
Strauss syndrome patients with heart involvement
ECG, electrocardiography; RBBB, right bundle branch block; LVEF, left
ventricle ejection fraction; VPC, ventricular premature complex; RAE, right
atrial enlargement; RWMA, regional wall motion abnormality.prognosis (15).
Renal involvement was absent in our patients. Although
it has been reported in CSS with variation across studies (0.3-
67%) (10, 12, 14-17), unlike other necrotizing vasculitis such
as WG or microscopic polyangiitis, renal failure is rare (11). 
A total of 24 biopsies were performed in 14 patients. Three
patients did not undergo any biopsy because of typical clini-
cal manifestation. Vasculitis was seen in 6 of 9 skin biopsies
(66.7%) and 6 of 7 nerve biopsies (85.7%). Therefore, the skin
and nerves seem to be useful as diagnostic biopsy sites.
Corticosteroids have been the cornerstone of treatment for
CSS since Chumbley et al. (17) reported a 5-yr survival rate
of 62% and a median survival of more than 9 yr after early
administration of corticosteroids. With acute multi-organ
involvement or poor predicted prognosis, treatment with 15
mg/kg intravenous methylprednisolone for 3 days followed
by 40-60 mg of prednisolone daily with gradual taper, has
been advocated (27-29). However, administration of high
dose corticosteroids for a long period has been known to com-
plicate treatment-related side effects. Immunosuppressive
agents such as immunoglobulin (30) or interferon (31) have
been added to the treatment of patients with severe multi-
organ involvement, unresponsiveness to corticosteroids, or
relapse. CPM, in particular, has improved prognosis and has
been recommended as adjuvant therapy in these patients (11,
29, 32). The benefit of pulse intravenous administration of
CPM versus oral CPM is debatable. A small clinical study of
25 patients with CSS compared daily oral CPM with monthly
intravenous CPM. The efficacy was comparable in both groups
and the side effect profile was twice as great in the group re-
ceiving oral administration; the researchers in this study rec-
ommended pulse intravenous therapy over daily oral therapy
for CSS (33). In very severe cases of CSS, corticosteroids and
CPM may be insufficient to induce remission. In these cases,
anti-TNF blocking agents such as infliximab or etanercept,
may be added for a limited period of time (34).
In the present study, initial clinical remission was achieved
in 16 patients (94.1%) and one patient (5.9%) died during
follow-up. Five patients (29.4%) suffered single relapse and
no suffered multiple relapses. The outcome in the present
study was similar to that in recent reports (14-16).
In conclusion, the main difference in manifestation of CSS
in this study compared to that in the previous studies was the
absence of renal involvement and lower detection rate for AN-
CA. The question of whether renal involvement and ANCA
are less present in Korean CSS patients needs to be answered
by in a large study. Additionally, favorable treatment outcome
in this study certainly needs further long-term study.
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